HUTCHMED (China) Ltd (HCM) Stock
HCM has an Alpha Score of 15 out of 100 (poor), computed on Nov 5, 2026 from 3 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported HCM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $1.40M. Its trailing P/E ratio is 127.8 and its net margin 3.3% (key statistics as of Nov 5, 2026).
What is HCM's Alpha Score?
How it works →Alpha Score of 15 reflects poor overall profile with poor momentum, poor value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own HCM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 130K | $1.40M | -1% |
| Citadel Ken Griffin | 38K | $409.5K | +25% |
| Millennium Management Israel Englander | 26K | $284.3K | -6% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are HCM's key statistics?
Key statistics as of Nov 5, 2026
How does HCM's valuation compare with the Healthcare sector?
| Metric | HCM | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 127.8 | 28.8 | 113 |
| Net margin | 3.26% | 3.66% | 170 |
| Return on equity | 1.43% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
HCM price chart
Powered by TradingViewWhat does HUTCHMED (China) Ltd do?
Hutchmed (China) Limited American Depositary Shares represent shares in HUTCHMED (China) Limited, an innovative, commercial-stage biopharmaceutical company. It specializes in the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company maintains a robust pipeline of small-molecule drugs, biologics, and antibody-targeted therapy conjugates (ATTCs) addressing specific molecular pathways such as VEGFR, MET, FGFR, and Syk. Key marketed products in China include ELUNATE (fruquintinib) for colorectal cancer, ORPATHYS (savolitinib) for non-small cell lung cancer, and SULANDA (surufatinib) for neuroendocrine tumors, supported by partnerships with companies like Eli Lilly and AstraZeneca. HUTCHMED operates through Oncology/Immunology and Other Ventures segments, with extensive commercial infrastructure in China and ongoing clinical studies worldwide. Founded in 2000 and headquartered in Hong Kong, it focuses on precision oncology and immunology, advancing candidates from in-house research to patient access globally.